We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) is launching an internet search portal this fall that will provide a centralized location to access clinical trial registries and databases worldwide.
An FDA draft guidance that proposes manufacturers conduct nonclinical safety studies on drug combinations, including adjunctive therapies, is excessive and needs to be further clarified, PhRMA said in recent comments submitted to the agency.
America’s drug safety network would be compromised if drug importation is legalized, says PhRMA, which points to new threats from countries whose regulatory systems allow for copycat drugs, known in Latin America as “similares.”
Changing the negative perception of the pharmaceutical industry will take two or three years, said the new head of PhRMA, who noted that member firms and the trade association already are taking steps to improve their image.
It will take two or three years to turn around the negative perception of the pharmaceutical industry, according to the new head of PhRMA, who says member firms and the trade association itself are already changing business practices that once drew fire.
PhRMA launched an enhanced and expanded version of its biopharmaceutical innovation website April 14 — part of its ongoing efforts to better educate the public about the industry’s drug-development efforts.
PhRMA launched an enhanced and expanded version of its biopharmaceutical innovation website April 14 — part of its ongoing efforts to better educate the public about the industry’s drug-development efforts.
A national coalition led by PhRMA will spend roughly $30 million through June to develop and promote a program that would help poor Americans gain access to the medicines they need.
The new head of PhRMA has vowed to do nothing less than “rescue and restore” the reputation of the pharmaceutical industry, which he says has not done enough to inform the public about its positive contributions to society.
PhRMA member companies invested a record $38.8 billion on pharmaceutical R&D in 2004, an increase of nearly 13 percent from the previous year, according to the association’s annual membership survey.